Elshad Hasanov, MD, PhD

Blessed to have an incredible clinic, lab team, and collaborators. This holiday season, we came together to paint our shared vision for the future: a colorful, beautiful, and healthy brain—free of metastasis. Grateful for this talented, passionate, and committed team making this dream possible for our patients and advancing cancer research. Here’s to more great work ahead! #LabFamily #HolidayCheer #NoBrainMetastasis @OSUCCC_James @OhioStateMedOnc @OSUWexMed

🚨🚨Multiple Brain Mets Randomized Trial🚨 · Significantly less symptom burden with SRS compared to HA-WBRT · Better ADL, cognition & KPS after SRS · SRS Standard of Care 5-20 brain mets jamanetwork.com/journals/jama/…

@DrKarineTawagi @arkhaki @PriyankaChabla1 @PGrivasMDPhD @oncologydoc @shilpaonc @ERPlimackMD @DrRosenbergMSK @koshkin85 @urotoday @oncodaily @BladderCancerUS @IBCG_BladderCA @WorldBladderCan The only available data so far would support the ICI rechallege after >1y of previous ICI @ESMO_Open @BrigidaMaiorano sciencedirect.com/science/articl…

Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity. pubmed.ncbi.nlm.nih.gov/41378983/

This interdisciplinary consensus effort sought to standardize practical management strategies of single & multiple brain mets in patients with #RenalCellCarcinoma. Authors present a framework to guide treatment decisions for patients. #AUC3 acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @OncoAlert

Mapping heterogeneity in the tumor microenvironment of #RenalCellCarcinoma through single-cell omics. #AuthorCommentary on UroToday, Single-cell and spatial technologies are uncovering profound heterogeneity in the #RCC tumor microenvironment—reshaping how we understand CD8⁺ T-cell exhaustion, myeloid diversity, and cancer-associated fibroblasts. These high-resolution insights are paving the way for better biomarkers and more precise, personalized immunotherapy in RCC. #ReadNow > bit.ly/4qYzI0Q @CellPressNews #TrendsinCancer @BetulGokYavuz1 @nkhanmam @ZuhairMajeed @mostafa96721868 @bilenma @eric_facs @HasanovLab

As 2025 comes to a close, @David_Cohn_MD, @DrRPollock and I thought we’d take a moment to celebrate stories this year that show why @OSUCCC_James is such a powerhouse against cancer. Here is a thread of 25 inspiring cancer stories in '25: 🧵

Happening now! The 7th Annual #PIIO Symposium Poster Session at Marriott OSU (3100 Olentangy River Rd, Cbus, OH). 🚀 Much more to come with the reception & Director's Address by Dr. @Zihai Li! @OSUCCC_James @Pelotonia #Immuno_Oncology

A perfect holiday-season read with hot chocolate & cookies ☕️🍪❄️ @trendscancer “Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics” Led by our rising star physician-scientist @BetulGokYavuz1 ✨ Free link: authors.elsevier.com/a/1mCdH8Z12ybX… Grateful for the @trendscancer editorial support, excellent reviewers, and our passionate team & collaborators @OhioStatePIIO @OSUCCC_James @OSUWexMed @KidneyCancer @kidneycan @IKCCorg 🙌

Kidney Cancer Highlights from ESMO 2025! @IKCCorg @myESMO #ESMO25 @OncoAlert @ONCOassist ikcc.org/summary-of-kid…

🚨 Breaking RCC update from Merck (Oct 28, 2025) Two back-to-back positive Phase 3 trials for belzutifan (WELIREG®) 👇 1️⃣ LITESPARK-022 – Adjuvant setting 📍 Pembrolizumab + Belzutifan vs Pembrolizumab alone ✅ Significant DFS improvement in resected clear-cell RCC after nephrectomy 🧩 1st combo ever to beat ICI monotherapy in adjuvant RCC OS pending 2️⃣ LITESPARK-011 – Post-IO metastatic setting 📍 Belzutifan + Lenvatinib vs Cabozantinib ✅ PFS benefit & higher ORR in patients who progressed after PD-1/L1 therapy ⚠️ OS trend but not yet significant @OncoAlert @MedwatchKate

Thank you to @OSUCCC_James brilient Urooncologist Dr. @eric_facs for arrenging this outstanding @KidneyCancer local meeting and let us to spend time with @Brutus_Buckeye as well and sharing our expertise. @ChristianRolfo @HasanovLab @KimrynRathmell @OSU_Urology @OhioStateMedOnc

Outstanding talk at @KidneyCancer local community talk from our @OSUCCC_James and @OhioStatePIIO raising star Dr. @HasanovLab (Elshad Hasanov) 🙏🎉👏 pelotonia.org/peloton/a0sQj0… @OhioStateMedOnc @OSU_Urology #KCA #KidneyCancer #OSUCCC #Oncology #Research #Collaboration #GUOnc

🕺🏻🥳🎉 !!WOW!! Brutus seriously knows how to jazz up a crowd! Thanks for bringing your energy to our #kidneycancer patient education event today! #GoBucks @OSUCCC_James @Brutus_Buckeye

Empowering You @KidneyCancer Patient Education Event: Inspiring and comprehensive morning session and panel discussion by @GEVaughan1 @eric_facs @fuatbcr @lingbin_meng @MartyMakary @shawndason @OSUWexMed @OSU_Urology Tremendous progress in the field, yet many important questions remain bringing us closer to a cure! 🧡🧫🔬💻💊

Excited to join our @KidneyCancer for the upcoming local #KidneyCancer meeting! Connecting clinicians, patients, and researchers to advance #RCC care and #PrecisionOncology 💪 @OhioStateCancer @OSU_Urology @OhioStateMedOnc @HasanovLab

🚨 Registration closes soon! kidneycancer.org/event/empoweri… Join the KCA and @OhioStateMedOnc next week — October 25 for a FREE #kidneycancer edu event. Hear directly from experts and connect with others who understand. Special thanks to @eric_facs @KimrynRathmell 🧡

Wonderful dinner with @eric_facs and our team! Great discussions and excitement for tomorrow’s patient event at @OSUCCC_James! kidneycancer.org/event/empoweri…

So excited to welcome everyone today to @OSUCCC_James for a patient education symposium! We have an exciting group of speakers to lead our discussions on treatment, disease management, patient experiences, and so much more. Thank you @OhioState for your partnership!